Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neumega in Hemophilia A and Von Willebrand Disease
NCT00994929Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Jan 2010
- Primary completion
- Apr 2012
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of oprelvekin in hemophilia A, von Willebrand disease (VWD), sponsored by University of Pittsburgh. Started Jan 2010; status: completed.
02
Drugs
oprelvekin
03
Conditions
hemophilia Avon Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT00994929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00994929.